ORIGINAL ARTICLE
Overexpression of kif11 is a poor prognostic factor in clear cell renal cell carcinoma
1
Chair and Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
2
Department of Tumor Pathology and Pathomorphology, Oncology Centre – Prof. Franciszek £ukaszczyk Memorial Hospital, Bydgoszcz, Poland
3
Division of Ophthalmology and Optometry, Department of Ophthalmology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
4
Department of Perinatology, Gynaecology and Gynaecologic Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
Submission date: 2021-10-01
Final revision date: 2022-02-16
Acceptance date: 2022-03-31
Publication date: 2022-07-15
Pol J Pathol 2022;73(2):82-87
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Unresectable renal cell carcinoma continues to be a great challenge due to our limited understanding of its underlying pathophysiology. We explored the relationship between KIF11 protein expression and the clinical courses of clear cell renal cell carcinoma (ccRCC) using a tissue microarray.
Material and methods:
The tissue microarray contained specimens derived from 90 patients, cancer and matched adjacent non-cancerous tissue (2 cores per case), followed up for 7 years. Tumour samples were evaluated for KIF11 expression using the H-score, and their correlations with clinicopathological data and survival data were analysed.
Results:
72.7% of ccRCC tissues presented KIF11 cytoplasmic expression with a median value of 20 (interquartile range 0–200). The nuclear staining was positive in 36.36% of ccRCC tissues. Among controls, nuclear KIF11 expression was absent, but cytoplasmic expression was identified in all cases, with a median value of 230 (interquartile range 45–290). Cytoplasmic KIF11 expression in ccRCC tissues was lower than in the control tissues and was positively correlated with tumour grade and mortality (p < 0.05). KIF11 nuclear expression did not correlate with overall survival.
Conclusions:
Elevated expression of KIF11 predicts poor clinical outcome in ccRCC patients. Downregulation of KIF11 may provide a new therapeutic strategy for ccRCC.
Unresectable renal cell carcinoma continues to be a great challenge due to our limited understanding of its underlying pathophysiology. We explored the relationship between KIF11 protein expression and the clinical courses of clear cell renal cell carcinoma (ccRCC) using a tissue microarray.
Material and methods:
The tissue microarray contained specimens derived from 90 patients, cancer and matched adjacent non-cancerous tissue (2 cores per case), followed up for 7 years. Tumour samples were evaluated for KIF11 expression using the H-score, and their correlations with clinicopathological data and survival data were analysed.
Results:
72.7% of ccRCC tissues presented KIF11 cytoplasmic expression with a median value of 20 (interquartile range 0–200). The nuclear staining was positive in 36.36% of ccRCC tissues. Among controls, nuclear KIF11 expression was absent, but cytoplasmic expression was identified in all cases, with a median value of 230 (interquartile range 45–290). Cytoplasmic KIF11 expression in ccRCC tissues was lower than in the control tissues and was positively correlated with tumour grade and mortality (p < 0.05). KIF11 nuclear expression did not correlate with overall survival.
Conclusions:
Elevated expression of KIF11 predicts poor clinical outcome in ccRCC patients. Downregulation of KIF11 may provide a new therapeutic strategy for ccRCC.
REFERENCES (33)
2.
Protzel C, Maruschke M, Hakenberg OW. Epidemiology, aetiology, and pathogenesis of renal cell carcinoma. Eur Urol 2012; 11: 52-59.
3.
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
4.
Wojcik EJ, Buckley RS, Richard J, et al. Kinesin-5: cross-bridging mechanism to targeted clinical therapy. Gene 2013; 531: 133-149.
5.
Imai T, Oue N, Nishioka M, et al. Overexpression of KIF11 in gastric cancer with intestinal mucin phenotype. Pathobiology 2016; 84: 16-24.
6.
Lu M, Zhu H, Wang X, et al. The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma. Pathology 2016; 48: 214-218.
7.
Sun XD, Shi XJ, Sun XO, et al. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta Pharmacol Sin 2011; 32: 1543-1548.
8.
Piao XM, Byun YJ, Jeong P, et al. Kinesin FAMILY MEMBER 11 mRNA expression predicts prostate cancer aggressiveness. Clin Genitourin Cancer 2017; 15: 450-454.
9.
Pei YY, Wang L, Li GC, et al. Kinesin family member 11 enhances the self-renewal ability of breast cancer cells by participating in the Wnt/-catenin pathway. J Breast Cancer 2019; 22: 522-532.
11.
Jin Q, Dai Y, Wang Y, et al. High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Clin Pathol 2019; 72.
13.
Pohl SG, Brook N, Agostino M, et al. Wnt signaling in triple-negative breast cancer. Oncogenesis 2017; 6: e310.
14.
Shi B, Bao J, Liu Y, Shi J. Death receptor 6 promotes ovarian cancer cell migration through KIF11. FEBS Open Bio 2018; 8: 1497-1507.
15.
Venere M, Horbinski C, Crish JF, et al. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 2015; 7: 304ra143.
16.
Ye XS, Fan L, Van Horn RD, et al. A novel Eg5 inhibitor (LY2523355) causes mitotic arrest and apoptosis in cancer cells and shows potent antitumor activity in xenograft tumor models. Mol Cancer Ther 2015; 14: 2463-2472.
17.
Zhou J, Chen WR, Yang LC, et al. KIF11 functions as an oncogene and is associated with poor outcomes from breast cancer. Cancer Res Treat 2019; 51: 1207-1221.
18.
Taglieri L, Rubinacci G, Giuffrida A, et al. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells. Invest New Drugs 2018; 36: 28-35.
19.
Truebenbach I, Zhang W, Wang Y, et al. Co-delivery of pretubulysin and siEG5 to EGFR overexpressing carcinoma cells. Int J Pharm 2019; 569: 118570.
20.
Davis DA, Sarkar SH, Hussain M, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006; 6.
21.
Algarín EM, Hernández-García S, Garayoa M, Ocio EM. Filanesib for the treatment of multiple myeloma. Expert Opin Investig Drugs 2020; 29: 5-14.
22.
Turajlic S, Xu H, Litchfield K, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 2018; 73: 581-594.e12.
23.
Kowalewski A, Zdrenka M, Grzanka D, Szylberg £. Targeting the deterministic evolutionary trajectories of clear cell renal cell carcinoma. Cancers (Basel) 2020; 12: 3300.
24.
Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 2018; 173: 595-610.e11.
25.
Joosten SC, Smits KM, Aarts MJ, et al. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol 2018; 15: 430-451.
26.
Pili R, Liu G, Chintala S, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. Br J Cancer 2017; 116: 874-883.
27.
Zibelman M, Wong YN, Devarajan K, et al. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs 2015; 33: 1040.
28.
Dasari A, Gore L, Messersmith WA, et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 2013; 31:115-125.
29.
Reu FJ, Soo IB, Cherkassky L, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006; 24: 3771-3779.
30.
Garzon R, Marcucci G, Croce CM . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775.
31.
Jones PA, Issa JPJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet 2016; 17: 630-641.
32.
Expression of KIF11 in renal cancer – The Human Protein Atlas. Available from: https://www.proteinatlas.org/E....
33.
Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science 2017; 357: eaan2507.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
